LFWD vs. VVOS, RVP, PETV, FEMY, ICU, IRIX, DRIO, NXGL, NRXS, and ALUR
Should you be buying Lifeward stock or one of its competitors? The main competitors of Lifeward include Vivos Therapeutics (VVOS), Retractable Technologies (RVP), PetVivo (PETV), Femasys (FEMY), SeaStar Medical (ICU), IRIDEX (IRIX), DarioHealth (DRIO), NexGel (NXGL), NeurAxis (NRXS), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry.
Lifeward vs. Its Competitors
Lifeward (NASDAQ:LFWD) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.
Vivos Therapeutics has a net margin of -99.49% compared to Lifeward's net margin of -121.80%. Lifeward's return on equity of -137.91% beat Vivos Therapeutics' return on equity.
In the previous week, Lifeward and Lifeward both had 2 articles in the media. Lifeward's average media sentiment score of 0.99 beat Vivos Therapeutics' score of 0.43 indicating that Lifeward is being referred to more favorably in the media.
26.8% of Lifeward shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.7% of Lifeward shares are owned by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Lifeward has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.03, suggesting that its share price is 603% more volatile than the S&P 500.
Lifeward presently has a consensus target price of $9.00, suggesting a potential upside of 1,351.38%. Vivos Therapeutics has a consensus target price of $4.82, suggesting a potential upside of 3.81%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than Vivos Therapeutics.
Vivos Therapeutics has lower revenue, but higher earnings than Lifeward. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.
Summary
Lifeward beats Vivos Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Lifeward News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFWD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LFWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lifeward Competitors List
Related Companies and Tools
This page (NASDAQ:LFWD) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access